A Federal Judge Spotted a Legal Contradiction in the Trans Military Ban
A federal judge is demanding answers from the Pentagon about a direct contradiction in how it applies hormone therapy to different service members. U.S. District Judge Ana Reyes, overseeing the Talbott v. United States case challenging Trump’s transgender military ban, ordered both parties on July 23, 2026, to explain why the Defense Department will fund testosterone replacement therapy (TRT) for cisgender male troops but deny the same treatment to transgender men.
The contradiction stems from two overlapping Pentagon policies. Defense Secretary Pete Hegseth announced last week a new annual screening program for “testosterone deficiency” in service members ages 30 and older. Troops under 30 can volunteer to be tested. Hegseth called the program necessary so troops can operate at their “absolute best.”
The transgender military ban, by contrast, bars service members from receiving hormone treatment, citing Trump’s executive order language that troops must maintain “high mental and physical health standards… without the benefit of routine medical treatment or special provisions.”
“The Department of Defense’s basis for treating trans men and other service members differently between this new policy and the Military Ban.”
Judge Ana Reyes, U.S. District Court for the District of Columbia, ordering the Pentagon to explain this distinction, July 23, 2026
Judge Reyes also ordered both parties to address “the similarities and differences in administering TRT, both medically and logistically, for trans men compared to other service members, including cis individuals.” The order is not a ruling. It is a demand for facts before the court decides next steps.
The Science Hegseth Cited Doesn’t Support the Policy Distinction
Testosterone levels decline naturally with age in men. The medical link between low testosterone and symptoms like mood changes, low libido, and fatigue is well established, though physicians have long debated how to diagnose deficiency and whether hormone replacement is the right treatment. Hegseth’s program would apply this same hormone to service members on the same voluntary basis that transgender men have requested for years.
Senate Democrats sent a letter the same day as Judge Reyes’s order demanding more information on the testosterone screening program. Their concern and the court’s concern overlap: the Pentagon has not produced a medical rationale for why TRT is appropriate for cisgender men experiencing natural testosterone decline but constitutes a “special provision” disqualifying transgender men from service.
Judge Reyes was nominated by President Joe Biden. Her order does not signal a ruling either way, but it puts the Pentagon on record explaining a policy inconsistency that now has formal legal standing.
What You Can Do Now
-
Call your senators at (202) 224-3121 and tell them to demand the Pentagon release the full medical justification for its testosterone screening program and explain why it excludes transgender service members from equivalent care.
-
Contact the Senate Armed Services Committee at (202) 224-3871. The committee has oversight authority over DOD medical programs. Ask members to hold hearings on the Pentagon’s differential treatment of hormone therapy.
-
Contact your House representative through house.gov/representatives/find-your-representative and ask them to cosponsor legislation protecting transgender service members from medical discrimination, specifically restoring equal access to medically necessary hormone treatment.
-
Find your state’s veterans’ service organizations at vfw.org or legion.org and urge them to issue statements supporting equal medical care for all service members, regardless of gender identity.
Sources
LGBTQ Nation: Judge Questions Why Hegseth Can Give Testosterone to Cis Men but Not Trans Men
Brennan Center for Justice: Transgender Military Ban Legal Challenges Overview
KFF: Testosterone Replacement Therapy and Military Medicine